Days af­ter con­tro­ver­sy greet­ed Bio­gen's block­buster Alzheimer's OK, the big biotech con­cedes a set­back on the tau front

Just days af­ter trig­ger­ing a mael­strom of con­tro­ver­sy with their de­ci­sion to launch an un­proven Alzheimer’s drug with a $56,000 price, Bio­gen $BI­IB is back with the lat­est da­ta on its mid-stage tau drug.

And it’s not good.

The big biotech says that go­suranemab — tar­get­ed at tau, the sec­ond lead­ing drug tar­get in Alzheimer’s — flat failed its Phase II and will now be tak­en out and dumped in the mass grave for all but one oth­er Alzheimer’s drug in the past gen­er­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER